Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.58 |
| ▸ | AXL | P30530 | 10/20 | 0.58 |
| ▸ | KDR | P35968 | 4/20 | 0.58 |
| ▸ | MERTK | Q12866 | 3/20 | 0.58 |
| ▸ | FLT1 | P17948 | 2/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | LYN | P07948 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | HCK | P08631 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372017 | 0.92 | MET (0.66) | METAXLKDRMERTKFLT1 | |
| SCHEMBL29883010 | 0.92 | MET (0.66) | METAXLKDRMERTKFLT1 | |
| Pyruvate SCHEMBL29195420 | 0.88 | MET (0.61) | METAXLKDRMERTKFLT1 | |
| SCHEMBL28694985 | 0.86 | MET (0.62) | METAXLKDRMERTKFLT1 | |
| SCHEMBL31105630 | 0.86 | MET (0.67) | METAXLKDRMERTKFLT1 | |
| Glutarate SCHEMBL29195414 | 0.86 | MET (0.58) | METAXLKDRMERTKFLT1 | |
| SCHEMBL21201003 | 0.85 | AXL (0.57) | METAXLKDRMERTKFLT1 | |
| SCHEMBL22750248 | 0.85 | AXL (0.57) | METAXLKDRMERTKFLT1 | |
| SCHEMBL29453833 | 0.85 | AXL (0.57) | METAXLKDRMERTKFLT1 | |
| SCHEMBL16061949 | 0.84 | KDR (0.56) | METAXLKDRMERTKFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20140155396-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. | 2014-06-05 | — | — | US | disclosed |
| EP-2139483-B1 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8497284-B2 | C-met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120022065-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2392564-A1 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022065-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885AXL 241/4885KDR 5/4885 |
| US-20140155396-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885AXL 241/4885KDR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.